生物制药公司Palvella Therapeutics宣布,其针对微囊性淋巴管畸形的在研药物Qtorin Rapamycin的新药申请正稳步推进,预计将按原定计划于2026年下半年提交监管机构。该时间表标志着公司在推进该创新疗法上市进程中迈出关键一步。
生物制药公司Palvella Therapeutics宣布,其针对微囊性淋巴管畸形的在研药物Qtorin Rapamycin的新药申请正稳步推进,预计将按原定计划于2026年下半年提交监管机构。该时间表标志着公司在推进该创新疗法上市进程中迈出关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.